ETARACIZUMAB: A DEEP REVIEW INTO MEDI523 AND LM609

Etaracizumab, formerly referred to as MEDI523 and then LM609, represents a unique method in antibody-mediated therapy. This humanized immunoglobulin is designed to precisely inhibit the activity of C1q, a vital component of the complement system involved in inflammation . Research have investiga